Anti Inflammatory News and Research

RSS

Regular exercise and drinking tea may reduce depression in breast cancer patients

Breast cancer patients who exercise and drink tea on a regular basis may be less likely to suffer from depression than other patients, according to a new study led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, Vanderbilt-Ingram Cancer Center. Xiaoli Chen, M.D., a post-doctoral fellow, was first author of the study published in the January issue of the Journal of Clinical Oncology.

28 Jan 2010

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

Cenestra Health announced today that the U.S. Patent and Trademark Office has issued a key patent related to the company's high-purity omega-3 fatty acid formulations and their methods of use. U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covers a unique, high-purity formulation of the omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).

27 Jan 2010

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the signing of a contract with YesDTC Holdings, Inc. (YESD.OB) to enter the Japanese market and receipt of the single largest product order and revenue commitment in company history.

26 Jan 2010

NicOx receives EMEA approval for naproxcinod MAA

NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.

22 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. have received a Paragraph IV Certification Notice from Watson Laboratories, Inc. advising of the filing of an Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM® (lidocaine topical patch 5%).

20 Jan 2010

Repeated exposure to tobacco smoke makes lung cancer much worse

Repeated exposure to tobacco smoke makes lung cancer much worse, and one reason is that it steps up inflammation in the lung. Scientists at the University of California, San Diego School of Medicine have found that mice with early lung cancer lesions that were repeatedly exposed to tobacco smoke developed larger tumors - and developed tumors more quickly - than unexposed animals.

19 Jan 2010

The Methodist Hospital initiates program on nanotechnology in orthopedics and spine surgery

A new research program at The Methodist Hospital in Houston is the nation's first dedicated solely to advancing nanotechnology in orthopedics and spine surgery.

19 Jan 2010

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Alcon, the world’s leader in eye care, announced today that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

18 Jan 2010

Allergan to jointly promote its adjustable gastric band for bariatric surgery with Covidien

Covidien, a leading global provider of healthcare products, today announced the extension of its agreement with Allergan, Inc. to jointly promote Allergan’s LAP-BAND® System, the top-selling adjustable gastric band for bariatric surgery, in the United States.

18 Jan 2010

Researchers identify six essential oils that can suppress inflammation

For those who do not drink, researchers have found that six essential oils -from thyme, clove, rose, eucalyptus, fennel and bergamot-can suppress the inflammatory COX-2 enzyme, in a manner similar to resveratrol, the chemical linked with the health benefits of red wine. They also identified that the chemical carvacrol was primarily responsible for this suppressive activity.

18 Jan 2010

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

18 Jan 2010

New findings may yield novel therapies for chronic neurodegenerative diseases

We all have at one time or another experienced the typical signs of an infection: the fever, the listlessness, the lack of appetite. They are orchestrated by the brain in response to circulating cytokines, the signaling molecules of the immune system. But just how cytokines' reach extends beyond the almost impenetrable blood-brain barrier has been the topic of much dispute.

18 Jan 2010

Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective

The current standard treatment for chronic hepatitis C with pegylated-interferon (PEG-IFN) and ribavirin is effective in approximately 50%-60% of patients, so that a substantial proportion of patients remain unresponsive.

18 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

NIH awards 12 research grants totaling $5 million for Tβ4 research

REGENERX BIOPHARMACEUTICALS, INC. announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tβ4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation.

13 Jan 2010

French maritime pine tree extract effective against hemorrhoids

According to the National Digestive Diseases Information Clearinghouse, about half of the U.S. population will have hemorrhoids by the age of 50. While the most common prescription to treat hemorrhoids is over-the-counter remedies, most patients do not report symptoms of acute hemorrhoidal attacks to their doctor until they are in severe distress, including bleeding.

12 Jan 2010

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

NicOx S.A. today announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis announced yesterday.

12 Jan 2010

Funxional Therapeutics completes Phase I study of FX125L

Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the Phase I programme of its novel anti-inflammatory, FX125L, an orally available small molecule that belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

8 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

Anti Inflammatory News and Research

Regular exercise and drinking tea may reduce depression in breast cancer patients

USPTO grants Cenestra Health patent relating to high-purity omega-3 fatty acid formulations

BioElectronics signs contract with YesDTC Holdings to enter the Japanese market

NicOx receives EMEA approval for naproxcinod MAA

Mice study shows obesity can increase risk of developing liver cancer

Endo Pharmaceuticals' partners receive Paragraph IV Certification Notice regarding LIDODERM

Repeated exposure to tobacco smoke makes lung cancer much worse

The Methodist Hospital initiates program on nanotechnology in orthopedics and spine surgery

Alcon to acquire U.S. rights to Sirion Therapeutics' Durezol and Zirgan

Allergan to jointly promote its adjustable gastric band for bariatric surgery with Covidien

Researchers identify six essential oils that can suppress inflammation

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

New findings may yield novel therapies for chronic neurodegenerative diseases

Treatment for chronic hepatitis C with pegylated-interferon and ribavirin proves effective

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

NIH awards 12 research grants totaling $5 million for Tβ4 research

French maritime pine tree extract effective against hemorrhoids

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

Funxional Therapeutics completes Phase I study of FX125L

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News